Update – Workpackage 4

We have been able to set up an innovative analysis pipeline to overcome the limitations of conventional approaches, and thus achieve our objective of defining a clinico-biological score for HAP classifying individual risk of  and predicting response to immunotherapy. Our clinico-biological score comprises 4 metabolites that can be used to classify patients into three levels of risk​ of HAP. This score is associated with response to interferon gamma 1b treatment. Our results will be published shortly.​

We thank the Pays de la Loire Region for making it possible to recruit a post-doctoral fellow, and for contributing to the development of predictive scores for hospital-acquired pneumonia and response to treatments.